Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2015
16th World Conference on Lung Cancer
Access to all presentations that occur during the 16th World Conference on Lung Cancer in Denver, Colorado
Presentation Date(s):- September 6 - 9, 2015
- Total Presentations: 2499
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
-
+
MINI 02 - Immunotherapy
- Type: Mini Oral
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 14
- Moderators:P. Forde
- Coordinates: 9/07/2015, 10:45 - 12:15, Four Seasons Ballroom F3+F4
-
+
MINI02.09 - ERK Activation Mediates Increased PD-L1 Expression in KRAS Mutated Premalignant Human Bronchial Epithelial Cells
11:30 - 11:35 | Author(s): M. Lee
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
ORAL 02 - PD1 Axis Immunotherapy 2
- Type: Oral Session
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 8
- Moderators:E.B. Garon
- Coordinates: 9/07/2015, 10:45 - 12:15, Four Seasons Ballroom F1+F2
-
+
ORAL02.01 - Phase 3, Randomized Trial (CheckMate 017) of Nivolumab (NIVO) vs Docetaxel in Advanced Squamous (SQ) Cell Non-Small Cell Lung Cancer (NSCLC)
10:45 - 10:56 | Author(s): K. Reckamp
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ORAL02.02 - Safety and Efficacy of Nivolumab in an Ongoing Trial of a PD-L1+/- Patient Population with Metastatic Non-Small Cell Lung Cancer
10:56 - 11:07 | Author(s): M. Hussein
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ORAL02.03 - Longer-Term Follow-Up of a Phase 2 Study (CheckMate 063) of Nivolumab in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
11:07 - 11:18 | Author(s): L. Horn
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ORAL02.04 - Discussant for ORAL02.01, ORAL02.02, ORAL02.03
11:18 - 11:28 | Author(s): S. Peters
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ORAL02.05 - Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
11:28 - 11:39 | Author(s): N.A. Rizvi
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ORAL02.06 - Evaluation of PD-L1 Expression in Metachronous Tumor Samples and FDG-PET as a Predictive Biomarker in Ph2 Study (FIR) of Atezolizumab (MPDL3280A)
11:39 - 11:50 | Author(s): J.E. Chaft
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ORAL02.07 - Atezolizumab (MPDL3280A) Combined with Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC): A Phase Ib Safety and Efficacy Update
11:50 - 12:01 | Author(s): R. Camidge
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ORAL02.08 - Discussant for ORAL02.05, ORAL02.06, ORAL02.07
12:01 - 12:11 | Author(s): G. Goss
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MINI 03 - PD1 Axis Inhibition and EGFR
- Type: Mini Oral
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 11
- Moderators:L. Gandhi
- Coordinates: 9/07/2015, 16:45 - 18:15, Four Seasons Ballroom F1+F2
-
+
MINI03.01 - Prior TKI Therapy in NSCLC EGFR Mutant Patients Associates with Lack of Response to Anti-PD-1 Treatment
16:45 - 16:50 | Author(s): E.B. Garon
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MINI03.03 - Pembrolizumab 2 mg/kg Q3W for Previously Treated, PD-L1-Positive Advanced NSCLC
16:55 - 17:00 | Author(s): O. Flotten
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MINI03.05 - Efficacy of Pembrolizumab in Key Subgroups of Patients with Advanced NSCLC
17:10 - 17:15 | Author(s): M.D. Hellmann
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MINI 09 - Drug Resistance
- Type: Mini Oral
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 14
- Moderators:L. Villaruz
- Coordinates: 9/07/2015, 16:45 - 18:15, 205+207
-
+
MINI09.06 - Oncogenic Drivers including RET and ROS1 plus PTEN Loss and MET by IHC in Patients with Lung Adenocarcinomas: Lung Cancer Mutation Consortium 2.0
17:15 - 17:20 | Author(s): B.E. Johnson
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MINI09.09 - Discussant for MINI09.06, MINI09.07, MINI09.08
17:30 - 17:40 | Author(s): E.B. Garon
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
ORAL 13 - Immunotherapy Biomarkers
- Type: Oral Session
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 8
- Moderators:D. Kim
- Coordinates: 9/07/2015, 16:45 - 18:15, Four Seasons Ballroom F3+F4
-
+
ORAL13.02 - Characterization of PD-L1 Expression Related to Unique Genes in NSCLC Tissue Samples
16:56 - 17:07 | Author(s): E.B. Garon
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 102
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.01-091 - Multicenter, Randomized, Double-Blind Study of Erlotinib plus Ramucirumab or Placebo in Patients with EGFR Mutation-Positive Metastatic NSCLC
09:30 - 09:30 | Author(s): E.B. Garon
- Abstract
Loading... -
+
P2.01-092 - A Phase IB Dose-Escalation Study of Pemetrexed and AUY922 in Previously Treated Metastatic Non-Squamous, Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): E.B. Garon
- Abstract
Loading...
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 91
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-087 - A Phase I Study of Exemestane with Carboplatin and Pemetrexed in Postmenopausal Women with Metastatic, Non-Squamous Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): R. Pietras
- Abstract
Loading...
-
+
ORAL 31 - PD1 Axis Inhibition
- Type: Oral Session
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 8
- Moderators:J. Weiss
- Coordinates: 9/09/2015, 16:45 - 18:15, Four Seasons Ballroom F1+F2
-
+
ORAL31.02 - Pembrolizumab for NSCLC: Immune-Mediated Adverse Events and Corticosteroid Use
16:56 - 17:07 | Author(s): N. Leighl
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ORAL31.05 - High Intratumoral T Cell Infiltration Correlated with Mutational Load and Response to Pembrolizumab in Non-Small Cell Lung Cancer
17:28 - 17:39 | Author(s): S. Hu-Lieskovan
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
